Kit for auxiliary diagnosis of multiple tumors by taking micro ribonucleic acid (RNA) combination as tumor marker, and detection method of kit

Abstract

The invention relates to a kit for auxiliary diagnosis of multiple tumors by taking a micro ribonucleic acid (RNA) combination as a tumor marker, and a detection method of the kit. The invention belongs to the fields of genetic engineering and oncology. The detection method comprises the steps of (1) extracting RNA from serum; (2) carrying out polyadenylation on the 3' end of micro RNA; (3) purifying and recovering a tailing product; (4) carrying out an inverse transcription reaction on the tailing product; (5) testing the relative expression of the micro RNA by means of a fluorescent quantitative PCR (polymerase chain reaction); (6) analyzing the result of the fluorescent quantitative PCR. The kit has the characteristics of high conservative property, space-time specificity, stability, tissue specificity and the like, and plays an important role in the aspects such as disease pathogenesis research, early diagnosis, individualized treatment and prognosis; furthermore, the kit is simple to operate, convenient in material obtaining, safe and noninvasive, and is conveniently used for screening of a great deal of diseases.

Description

technical field [0001] The invention belongs to the fields of genetic engineering and oncology, and relates to serum microRNA markers related to various human tumors and applications thereof. Background technique [0002] "Talking about the discoloration of cancer" is the number one attitude of most people towards cancer; cancer has always been a chronic disease that threatens human health and even life; on January 25, 2016, the world's top magazine in the field of cancer "CA: CA Cancer J Clin published online the 2015 cancer statistics released by the National Cancer Center, which shows that in 2015, there are expected to be 4.292 million new cancer cases and 2.814 million deaths in China, equivalent to an average of 12,000 per day. New cancer cases and 7,500 deaths from cancer; in view of this, we urgently need to explore new methods of tumor diagnosis and treatment. [0003] microRNA, also known as micro ribonucleic acid, is a kind of non-coding single-stranded small rib...

AI Technical Summary

Problems solved by technology

[0006] Traditional tumor detection markers are mostly hormones and proteins, such as human chorionic gonadotropin (HCG); adrenocorticotropic hormone (ACTH); alpha-fetoprotein (AFP); carcinoembryonic antigen (CEA); glycoprotein ( CA125) and squamous cell carcinoma-associated antigen (SCC), etc., but the shortcomings of traditional tumor markers compared with microRNA as tumor markers are: (1) Traditional tumor markers cannot be accurately detected in the early stage of tumor development, mostly in the Auxiliary diagnosis in the middle and late stage; (2) The detection is mostly carried out on tumor lesion tissue, which cannot reach the level of non-invasiveness; (3) The accuracy of the detection result is not high; (4) The detection is not convenient enough, and the steps are complicated; (5) The detection cannot be carried out Real-time monitoring, etc. Therefore, microRNA as a tumor marker has great advantages in early diagnosis and has become a research hotspot. According to data and related research, prostate cancer, colorectal cancer, gastric cancer, lung cancer, ovarian cancer, and DLBCL diffuse large B Cellular lymphoma, CLL chronic lymphocytic leukemia, liver cancer, kidney cancer, pancreatic cancer, breast cancer, esophageal cancer, leukemia, and squamous cell carcinoma of the tongue are all regulated by a variety of microRNAs, and some indicate that these microRNAs may be useful for the diagnosis of related tumors It has an indication function and can be regarded as a potential tumor marker for the diagnosis of the above-mentioned cancers; however, the above-mentioned microRNA combination is currently used as a relatively stable biomarker for the auxiliary early diagnosis of various cancers and the corresponding auxiliary early diagnosis kits have not yet been developed. see the report

Images